A Comparative Analysis of Eradication Success, Side Effects, and Adherence in Pediatric Patients Treated with Triple Therapy Versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Infection - Scorecard - MDSpire
Advertisement
A Comparative Analysis of Eradication Success, Side Effects, and Adherence in Pediatric Patients Treated with Triple Therapy Versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Infection
Clinical Scorecard: A Comparative Analysis of Eradication Success, Side Effects, and Adherence in Pediatric Patients Treated with Triple Therapy Versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Infection
At a Glance
Category
Detail
Condition
Helicobacter pylori infection in pediatric patients
Key Mechanisms
Triple therapy uses PPI, clarithromycin, and amoxicillin; bismuth-containing quadruple therapy adds colloidal bismuth subcitrate which has antimicrobial effects disrupting bacterial protein synthesis, membranes, and adherence
Target Population
Children diagnosed with H. pylori infection and chronic gastritis
Care Setting
Pediatric gastroenterology outpatient and inpatient settings
Key Highlights
Bismuth-containing quadruple therapy achieved a significantly higher eradication rate (90.36%) compared to triple therapy (74.36%)
Symptom improvement (abdominal pain, bloating, nausea) was greater with bismuth-containing quadruple therapy
Adverse event incidence and medication compliance rates were comparable between both therapies
Guideline-Based Recommendations
Diagnosis
Confirm H. pylori infection via rapid urease test and histopathological examination of gastric biopsies obtained during upper GI endoscopy
Management
Consider bismuth-containing quadruple therapy as a first-line treatment in pediatric H. pylori infection to improve eradication rates and symptom relief
Standard triple therapy remains an option but may have lower efficacy due to antibiotic resistance
Monitoring & Follow-up
Assess eradication success using 13C-urea breath test 4 weeks post-treatment
Monitor symptom scores (abdominal pain, bloating, nausea) before and after treatment
Track adverse events and medication adherence during therapy
Risks
Antibiotic resistance may reduce triple therapy efficacy
Adverse events are similar between triple and bismuth-containing quadruple therapies
Ensure compliance to maximize eradication success
Patient & Prescribing Data
Pediatric patients with confirmed H. pylori infection undergoing 14-day eradication therapy
Bismuth-containing quadruple therapy offers higher eradication rates and better symptom relief without increased adverse events or reduced compliance compared to triple therapy
Clinical Best Practices
Use combined diagnostic methods (RUT and histopathology) to confirm H. pylori infection in children
Prefer bismuth-containing quadruple therapy to overcome antibiotic resistance and improve eradication success
Monitor symptoms and adverse events closely to ensure treatment tolerability
Educate patients and caregivers to maintain high medication adherence
Reassess eradication status with non-invasive breath testing 4 weeks after therapy completion
